Synapse - Paul Hamlin

Results (293)

Influence of post-second-line chemotherapy PET Imaging and involved field radiotherapy prior to high dose therapy on outcomes of relapsed or refractory diffuse large B cell lymphoma

Meeting Abstract

Hoppe, B. S.; Moskowitz, C. H.; Zhang, Z.; Kewalramani, T.; Maragulia, J. C.; Rice, R. D.; Reiner, A. S.; Hamlin, P. A.; Zelenetz, A. D.; Yahalom, J.
International Journal of Radiation Oncology, Biology, Physics (2008)

Fulltext@MSK | Save

Sequential RCHOP and yttrium-90 ibritumomab tiuxetan (RIT) is a highly effective regimen for high risk elderly patients with untreated DLBCL

Meeting Abstract

Hamlin, P. A.; Moskowitz, C. H.; Wegner, B.; Noy, A.; Gerecitano, J.; Palomba, M. L.; Portlock, C.; Straus, D.; Pro, B.; Fayad, L.; more...
Annals of Oncology (2008)

Fulltext@MSK | Save

Bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P): Two dosing schedules of a novel phase I regimen in patients with relapsed/refractory indolent and mantle cell lymphomas

Meeting Abstract

Gerecitano, J.; Portlock, C.; Hamlin, P.; Moskowitz, C.; Noy, A.; Straus, D.; Zelenetz, A. D.; Schulman, P.; Dumitrescu, O.; O'Connor, O. A.
Annals of Oncology (2008)

Fulltext@MSK | Save

A placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T (ID-KLH) and GM-CSF following rituximab in patients with CD20+ follicular lymphoma

Meeting Abstract

Freedman, A. S.; Neelapu, S.; Nichols, C. R.; Robertson, M.; Djulbegovic, B.; Winter, J. N.; Gold, D.; Bender, J.; Stewart, M.; Ghalie, R. G.; more...
Blood (2008)

Fulltext@MSK | Save

Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): Developing a lymphoma prevention strategy

Journal Article

Portlock, C. S.; Hamlin, P.; Noy, A.; Chey, W.; Gaydos, C. A.; Palomba, L.; Schwartz, I.; Corcoran, S.; Rosenzweig, L.; Walker, D.; more...
Annals of Oncology (2008)

Fulltext@MSK | Save

A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma

Journal Article

O'Connor, O. A.; Portlock, C.; Moskowitz, C.; Straus, D.; Hamlin, P.; Stubblefield, M.; Dumitrescu, O.; Colevas, A. D.; Grant, B.; Zelenetz, A.
British Journal of Haematology (2008)

Fulltext@MSK | Save

A phase '2-1-2' study of two different doses and schedules of pralatrexate, a high affinity substrate for the reduced folate carrier (RFC-1), in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies

Meeting Abstract

O'Connor, O. A.; Hamlin, P.; Portlock, C.; Moskowitz, C.; Noy, A.; Straus, D.; Dumetrescu, O.; Sarasohn, D.; Neylon, E.; Hamelers, R.; more...
Molecular Cancer Therapeutics (2007)

Fulltext@MSK | Save

Predictors of distress in older patients with cancer

Meeting Abstract

Li, D.; Patil, S.; Nelson, C.; Lichtman, S.; Tew, W.; Hamlin, P.; Zuckerman, E.; Gardes, J.; Limaye, S.; Kelly, E.; more...
Journal of the American Geriatrics Society (2007)

Fulltext@MSK | Save

Results from phase 1 dose escalation study of the proteasome inhibitor NPI-0052 in patients with solid tumors and lymphomas

Meeting Abstract

Kurzrock, R.; Hamlin, P.; Younes, A.; Hong, D.; Gordon, M.; Hannah, A.; Palladino, M. A.; Lloyd, G. K.; Longenecker, A. M.; Neuteboom, S. T. C.; more...
Molecular Cancer Therapeutics (2007)

Fulltext@MSK | Save

Phase 1 clinical trial of a novel proteasome inhibitor (NPI-0052) in patients with lymphomas and solid tumors

Meeting Abstract

Kurzrock, R.; Hamlin, P.; Younes, A.; Hong, D.; Gordon, M.; Spear, M. A.; Palladino, M. A.; Lloyd, G. K.; Longenecker, A. M.; Neuteboom, S. T. C.; more...
Blood (2007)

Fulltext@MSK | Save